©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2024; 15(5): 594-598
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.594
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.594
Navigating breast cancer brain metastasis: Risk factors, prognostic indicators, and treatment perspectives
Jayalingappa Karthik, Amit Sehrawat, Mayank Kapoor, Deepak Sundriyal, Department of Medical Oncology Haematology, All India Institute of Medical Sciences Rishikesh, Rishikesh 249203, Uttarakhand, India
Author contributions: Karthik J and Sehrawat A designed the overall concept and outline of the manuscript, and contributed to writing and editing the manuscript, and review of the literature; Kapoor M and Sundriyal D contributed to the discussion and design of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interest.
Corresponding author: Amit Sehrawat, MBBS, MD, DrNB, Associate Professor, Department of Medical Oncology Haematology, All India Institute of Medical Sciences Rishikesh, Virbhadra Road, Rishikesh 249203, India. dramitsehrawat@gmail.com
Received: January 5, 2024
Revised: January 24, 2024
Accepted: April 15, 2024
Published online: May 24, 2024
Processing time: 136 Days and 15.4 Hours
Revised: January 24, 2024
Accepted: April 15, 2024
Published online: May 24, 2024
Processing time: 136 Days and 15.4 Hours
Core Tip
Core Tip: Breast cancer brain metastasis management faces many challenges. Key risk factors include HER-2 positivity, triple-negative subtype, and germline BRCA mutation. Limited predictive models emphasize the need for validated nomograms. Current guidelines recommend screening when symptomatic. Chen et al highlight HER-2 and triple-negative associations, impacting treatment strategies. Proactive research is crucial for preventive strategies, blood-brain barrier-penetrating therapies, and validated predictive models.